| Literature DB >> 27391045 |
Po-Ching Chi1,2,3,4, Shun-Chuan Chang3, Chun-Ho Yun4,5, Jen-Yuan Kuo1,2,3, Chung-Lieh Hung1,2,3,4,5, Charles Jia-Yin Hou1,2,3,4,5, Chia-Yuan Liu6, Fei-Shih Yang5, Tung-Hsin Wu7, Hiram G Bezerra8, Hung-I Yeh1,2,3.
Abstract
BACKGROUND: The associations between pericardial adiposity and altered atrial conduction had been demonstrated. However, data comparing differential effects of various body sites visceral adiposity on atrial and ventricular electrocardiographic alterations remains largely unknown. METHODS ANDEntities:
Mesh:
Year: 2016 PMID: 27391045 PMCID: PMC4938552 DOI: 10.1371/journal.pone.0158300
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1The illustration of single PCF (A) or TAT (C) slice re-construction by using dedicated CT software (Aquarius 3D Workstation, TeraRecon, San Mateo, CA, USA) and subsequent semi-automatic 3D volumes (B: PCF, D: TAT) using CT dataset by summation methods in our current study.
Baseline demographic data of all study subjects based on visceral adiposity (either PCF or TAT) stratification in current study.
| PCF, ml (25th -75th) | Q1: 34.04~45.94 | Q2: 54.15~61.05 | Q3: 67.59~74.95 | Q4: 83.16~93.18 | Q5: 105.75~134 | p for trend |
|---|---|---|---|---|---|---|
| Age, years | 45.25±9.31 | 48.6±8.83 | 49.71±9.02 | 50.95±9.5 | 53.66±9.89 | <0.001 |
| Gender, male (%) | 321(10.40%) | 429(13.90%) | 468(15.16%) | 498(16.13%) | 521(16.88%) | <0.001 |
| Weight, kg | 59.44±10.23 | 65.11±11.37 | 68.98±10.72 | 71.73±12.46 | 76.77±12.32 | <0.001 |
| BMI, kg/m2 | 22.16±2.84 | 23.59±3.35 | 24.69±2.95 | 25.66±3.62 | 27.47±8.32 | <0.001 |
| SBP, mmHg | 117.17±17.29 | 119.96±19.6 | 123.94±17.36 | 123.39±19.16 | 127.39±19.3 | <0.001 |
| WBC Count, X 103/mm3 | 5.83±1.62 | 6.13±1.63 | 6.19±1.55 | 6.4±1.57 | 6.56±1.59 | <0.001 |
| Fasting Glucose, mg/dL | 94.24±13.47 | 98.8±17.05 | 102.79±24.36 | 104.36±22.42 | 108.51±28.7 | <0.001 |
| Cholesterol, mg/dL | 194.03±33.24 | 201.28±39.96 | 206.03±34.52 | 203.93±35.81 | 204.86±37.86 | <0.001 |
| Triglyceride, mg/dL | 104.85±63.57 | 134.82±176.28 | 144.93±88.12 | 154.04±97.79 | 171.03±116.53 | <0.001 |
| LDL, mg/dL | 121.18±30.03 | 129.94±31.94 | 134.81±31.17 | 133.82±32.74 | 134.06±33.36 | <0.001 |
| HDL, mg/dL | 59.21±15.32 | 53.79±13.78 | 51.85±13.36 | 49.32±11.33 | 47.02±11.99 | <0.001 |
| eGFR, mL/min/1.73m2 | 86.69±15.69 | 82.7±14.19 | 81.48±13.67 | 81.36±15.41 | 79.95±15.65 | <0.001 |
| Hypertension, % | 45(7.3%) | 82(13.3%) | 106(17.1%) | 116(18.8%) | 157(25.5%) | <0.001 |
| Diabetes, % | 13(2.1%) | 35(5.7%) | 30(4.9%) | 39(6.3%) | 56(9.1%) | <0.001 |
| Hyperlipidemia, % | 15(2.4%) | 37(6%) | 36(5.8%) | 51(8.3%) | 74(12%) | <0.001 |
| CVD, % | 12(2%) | 20(3.3%) | 20(3.2%) | 36(5.8%) | 46(7.5%) | <0.001 |
| Alcohol use, % | 29(4.7%) | 30(4.9%) | 35(5.7%) | 43(7%) | 43(7%) | 0.241 |
| Smoking, % | 49(7.9%) | 58(9.4%) | 71(11.5%) | 86(14%) | 95(15.4%) | <0.001 |
Abbreviations: BMI: body mass index, CVD: cardiovascular diseases, eGFR: estimated glomerular filtration rate, HDL: high density apo-lipoprotein, LDL: low density apo-lipoprotein, PCF: pericardial fat, SBP: systolic blood pressure, TAT: peri-aortic adipose tissue, WBC: white blood cell count.
Baseline demographic data of all study subjects based on visceral adiposity (PCF and TAT) stratification in current study.
| TAT, ml (25th -75th) | Q1: 2.29~3.25 | Q2: 4.14~5.07 | Q3: 5.96~6.87 | Q4: 7.82~9.14 | Q5: 10.93~14.57 | p for trend |
|---|---|---|---|---|---|---|
| Age, years | 48.33±8.88 | 50.6±9.32 | 51.09±9 | 53.17±9.02 | 54.97±9.04 | <0.001 |
| Gender, male (%) | 87(32.83%) | 188(70.41%) | 226(85.28%) | 240(90.23%) | 257(96.98%) | <0.001 |
| Weight, kg | 57.32±8.68 | 65.63±9.69 | 69.91±9.93 | 72.49±10.03 | 78.22±11.47 | <0.001 |
| BMI, kg/m2 | 21.89±2.76 | 23.73±2.63 | 24.91±2.98 | 25.68±2.94 | 27.35±3.38 | <0.001 |
| SBP, mmHg | 115.11±16.52 | 121.73±16.89 | 123.9±15.54 | 127.36±14.89 | 128.71±16.31 | <0.001 |
| WBC Count, X 103/mm3 | 5.62±1.49 | 6.01±1.55 | 6.22±1.58 | 6.55±1.57 | 6.72±1.63 | <0.001 |
| Fasting Glucose, mg/dL | 93.14±11.26 | 98.03±16.05 | 101.81±22.83 | 102.7±20 | 112.99±31.43 | <0.001 |
| Cholesterol, mg/dL | 195.77±35.08 | 201.89±35.54 | 204.3±36.46 | 204.88±38.71 | 203.24±36.32 | <0.001 |
| Triglyceride, mg/dL | 94.54±55.62 | 125.4±72.15 | 142.73±86.89 | 162.99±178.58 | 183.95±126.25 | <0.001 |
| LDL, mg/dL | 121.2±31.32 | 130.09±32.23 | 135.13±32.31 | 135.35±30.82 | 132.28±32.5 | <0.001 |
| HDL, mg/dL | 62.37±15.43 | 55.22±13.57 | 50.69±12.18 | 47.44±10.01 | 45.4±10.2 | <0.001 |
| eGFR, mL/min/1.73m2 | 87.4±15.06 | 84.39±15.56 | 82.03±13.92 | 80.62±13.86 | 77.7±15.28 | <0.001 |
| HTN, % | 38(6.1%) | 67(10.9%) | 83(13.5%) | 115(18.6%) | 203(33%) | <0.001 |
| DM, % | 12(1.9%) | 20(3.3%) | 35(5.7%) | 36(5.8%) | 70(11.4%) | <0.001 |
| Hyperlipidemia, % | 15(2.4%) | 32(5.2%) | 46(7.5%) | 50(8.1%) | 70(11.4%) | <0.001 |
| CVD, % | 11(1.8%) | 29(4.7%) | 24(3.9%) | 23(3.7%) | 47(7.6%) | <0.001 |
| Alcohol use, % | 21(3.4%) | 26(4.2%) | 33(5.4%) | 44(7.1%) | 56(9.1%) | <0.001 |
| Smoking, % | 31(5%) | 54(8.8%) | 72(11.7%) | 96(15.5%) | 106(17.2%) | <0.001 |
Several body surface 12-lead ECG parameters across visceral adiposity stratification measures (PCF and TAT) in current study
| P Axis,° | 54.77±24.38 | 52.01±22.5 | 48.49±25.78 | 45.56±25.87 | 43.76±23.38 | <0.001 |
| PR Interval, ms | 160.38±19.89 | 163.95±18.99 | 164.97±20.29 | 166.54±20.04 | 170.69±20.89 | <0.001 |
| QRS Axis,° | 58.78±34.51 | 52.58±38 | 51.13±37.6 | 44.21±39.17 | 42.04±42.9 | <0.001 |
| QRS Duration, ms | 85.65±8.89 | 87.58±8.3 | 88.89±8.8 | 88.98±8.53 | 90.58±8.52 | <0.001 |
| P Axis,° | 52.73±26.59 | 51.53±25.12 | 50.69±23.97 | 46.51±24.52 | 43.25±22.04 | <0.001 |
| PR Interval, ms | 158.08±18.68 | 163.33±19.84 | 165.08±19.97 | 168.57±18.8 | 171.38±21.54 | <0.001 |
| QRS Axis,° | 58.48±33.52 | 53.46±38.5 | 51.78±36.06 | 46.21±39.3 | 38.84±43.92 | <0.001 |
| QRS Duration, ms | 85.14±8.86 | 88±8.36 | 88.34±8.62 | 89.96±8.48 | 90.2±8.53 | <0.001 |
Fig 2The associations between PCF or TAT on several electrocardiographic indices, including PR interval, QRS duration and QRS axes.
No sex interactions were observed n these associations.
The associations between visceral adiposity and body surface ECG data in uni-variate and multi-variate models
| Coef | SE | p value | Coef | SE | p value | Coef | SE | p value | Coef | SE | p value | ||
| P Axis,° | -6.53 | 0.70 | <0.001 | -4.54 | 0.54 | <0.001 | P Axis,° | -7.85 | 0.76 | <0.001 | -6.82 | 0.65 | <0.001 |
| PR Interval, ms | 6.22 | 0.58 | <0.001 | 5.84 | 0.44 | <0.001 | PR Interval, ms | 3.25 | 0.61 | <0.001 | 2.90 | 0.52 | <0.001 |
| QRS Axis,° | -8.94 | 1.05 | <0.001 | -8.96 | 0.81 | <0.001 | QRS Axis,° | -6.21 | 1.14 | <0.001 | -7.91 | 0.97 | <0.001 |
| QRS Duration, ms | 2.52 | 0.32 | <0.001 | 2.06 | 0.24 | <0.001 | QRS Duration, ms | 1.71 | 0.34 | <0.001 | 0.65 | 0.29 | 0.025 |
| Coef | SE | p value | Coef | SE | p value | Coef | SE | p value | Coef | SE | p value | ||
| P Axis,° | -5.05 | 0.81 | <0.001 | -4.23 | 0.70 | <0.001 | P Axis,° | -4.48 | 0.87 | <0.001 | -3.54 | 0.77 | <0.001 |
| PR Interval, ms | 2.04 | 0.66 | 0.002 | 1.79 | 0.57 | 0.002 | PR Interval, ms | 1.80 | 0.71 | 0.011 | 1.3 | 0.63 | 0.037 |
| QRS Axis,° | -3.82 | 1.22 | 0.002 | -6.08 | 1.06 | <0.001 | QRS Axis,° | -3.04 | 1.29 | 0.019 | -4.72 | 1.16 | <0.001 |
| QRS Duration, ms | 1.64 | 0.33 | <0.001 | 0.43 | 0.29 | 0.132 | QRS Duration, ms | 1.69 | 0.36 | <0.001 | 0.36 | 0.27 | 0.171 |
Model 1: adjusted for age, gender;
Model 2: adjusted for age, gender, BMI;
Model 3: adjusted for age, gender, BMI, SBP, Pulse rate, HDL, LDL, eGFR, hypertension, diabetes, cardiovascular disease, current smoking and alcohol use.
† in which models BMI was significant (p<0.05).
Fig 3Likelihood ratio tests demonstrated the incremental value of PCF and TAT in identifying body surface 12-leads ECG anomaly, including prolonged PR interval (>200ms) and QRS duration (>100ms) when superimposed on age and body size measure in terms of BMI.